Involvement of DR4/JNK pathway-mediated autophagy in acquired TRAIL resistance in HepG2 cells
Sung-Chul Lim1, Ho Jong Jeon1, Keun Hong Kee1
1Department of Pathology, College of Medicine, Chosun University, Gwangju 61501, Republic of Korea.
Abstract:
Although tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent, a number of cancer cells demonstrate TRAIL resistance. To date, various molecular targets leading to TRAIL resistance have been elucidated by many researchers, but the mechanisms involved are still not fully understood. In the present study, we obtained TRAIL-resistant cells from the human hepatocellular carcinoma cell line HepG2 by exposing cells to recombinant human TRAIL (rhTRAIL), and determined a mechanism for TRAIL resistance. The selected TRAIL-resistant cells (HepG2-TR) were insensitive to rhTRAIL and triggered autophagy in response to rhTRAIL. The inhibition of autophagy by 3-methyladenine or the knockdown of ATG5 partially restored rhTRAIL-induced apoptosis and cytotoxicity, indicating that protective autophagy occurred in the cells. Notably, rhTRAIL-induced autophagy was mediated through DR4 in HepG2-TR cells, but not in parental HepG2 cells. In addition, the c-Jun N-terminal kinase was involved in DR4-mediated autophagy in HepG2-TR cells. Our results suggest a novel mechanism of TRAIL resistance which is regulated through alterations in DR4 function, which may extend our understanding of the mechanisms of TRAIL resistance.
Insights
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance in cancer cells can be overcome by targeting protective autophagy. This study reveals TRAIL-induced autophagy mediated by DR4 in resistant HepG2 cells, offering new therapeutic strategies.
Area of Science:
- Oncology
- Molecular Biology
- Cellular Biology
Background:
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows promise as an anticancer agent.
- TRAIL resistance is a significant challenge in cancer therapy, with mechanisms not fully understood.
Purpose of the Study:
- To elucidate a novel mechanism of TRAIL resistance in hepatocellular carcinoma cells.
- To investigate the role of autophagy and DR4 in TRAIL resistance.
Main Methods:
- Generation of TRAIL-resistant HepG2 cells (HepG2-TR) by exposure to recombinant human TRAIL (rhTRAIL).
- Assessment of apoptosis and cytotoxicity in response to rhTRAIL.
- Inhibition of autophagy using 3-methyladenine and ATG5 knockdown.
- Analysis of DR4 and c-Jun N-terminal kinase involvement.
Main Results:
- HepG2-TR cells exhibited insensitivity to rhTRAIL and triggered autophagy.
- Inhibition of autophagy partially restored rhTRAIL-induced apoptosis and cytotoxicity, indicating protective autophagy.
- rhTRAIL-induced autophagy was mediated by DR4 in HepG2-TR cells, involving c-Jun N-terminal kinase.
Conclusions:
- A novel mechanism of TRAIL resistance involving DR4-mediated, c-Jun N-terminal kinase-regulated autophagy has been identified.
- These findings enhance the understanding of TRAIL resistance and suggest potential therapeutic targets.
More Related Videos
Related Concept Videos
Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
MAPK Signaling Cascades
PI3K/mTOR/AKT Signaling Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...


